ReviewJournal of translational medicine2012
Cancers of unknown primary origin: current perspectives and future therapeutic strategies.
Review in Journal of translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02628379 (A Prospective Observational Trial Evaluating Outcomes of FoundationOne - Directed Matched Targeted Therapy in Patients With Cancer of Unknown Primary), which is not on this map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Observational Trial Evaluating Outcomes of FoundationOne - Directed Matched Targeted Therapy in Patients With Cancer of Unknown Primary (CUP)
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.Frontiers in oncology · 2020Pooled it
- A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.The oncologist · 2021Trial
- Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Diagnostic Utility of a 90-Gene Expression Assay (Canhelp-Origin) for Patients with Metastatic Cancer with an Unclear or Unknown Diagnosis.Molecular diagnosis & therapy · 2025Article
- A Case of Carcinoma Metastasis of Unknown Primary Mimicking Spondylodiscitis in an HIV+ Patient.Cureus · 2024Article
- A case of laparoscopic lymphadenectomy for adenocarcinoma of unknown primary incidentally detected as a solitary enlarged lymph node along the common hepatic artery.Surgical case reports · 2024Article
- Rare axillary cancer of unknown primary originating from the breast of a 64‑year‑old male patient: A case report and literature review.Oncology letters · 2024Article
- Lung bronchiectasisas a paradigm of the interplay between infection and colonization on plastic modulation of the pre-metastatic niche.Frontiers in oncology · 2024Article
- Interstitial lung diseases with concomitant lung cancer: a data mining approach revealing a complex condition with gender- and immune-associated specific implications.Frontiers in oncology · 2024Article
- Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.ESMO open · 2023Article
- Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.BMC cancer · 2023Article
- Carcinoma of unknown primary (CUP): an update for histopathologists.Cancer metastasis reviews · 2023Review
- Assessing the utility of molecular diagnostic classification for cancers of unknown primary.Cancer medicine · 2023Article
- Occult breast cancer with pleural metastasis.Radiology case reports · 2023Article
- Metastatic carcinoma of unknown origin in a dog.The Canadian veterinary journal = La revue veterinaire canadienne · 2023Article
- Article
- Multidisciplinary Approach to the Diagnosis of Occult Primary Neuroendocrine Neoplasm: A Clinical Challenge.Journal of clinical medicine · 2023Review
- The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints.International journal of molecular sciences · 2023Review
- Role of Whole body PET/CT and Examination under anesthesia with multi-site biopsy in evaluating CUP.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes, rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of a clearly detectable primary mass. This kind of disease is referred to as cancer of unknown primary (CUP) origin and accounts for 3-5% of all cancer diagnosis. There is poor consensus on the extent of diagnostic and pathologic evaluations required for these enigmatic cases which still lack effective treatment. Although technology to predict the primary tumour site of origin is improving rapidly, the key issue is concerning the biology which drives early occult metastatic spreading. This review provides the state of the art about clinical and therapeutic management of this malignant syndrome; main interest is addressed to the most recent improvements in CUP molecular biology and pathology, which will lead to successful tailored therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.